0000000000599018

AUTHOR

D. Sacchini

showing 5 related works from this author

Epidemiological evolution of Chronic Hepatitis Delta in Italy. An analysis of the Master-B cohort

2014

Deltamedicine.medical_specialtyPediatricsHepatologyChronic hepatitisbusiness.industryEpidemiologyCohortGastroenterologymedicinebusinessDigestive and Liver Disease
researchProduct

The importance of HCV on the burden of chronic liver disease in Italy: a multicenter prevalence study of 9,997 cases

2005

Knowledge of the current epidemiology of chronic liver disease in Italy is mostly obsolete and fragmentary for the lack of up-to-date consistent data. In 2001, a 6-month prevalence study was undertaken in 79 hospitals to assess the characteristics of chronic liver disease in Italy. Both prevalent and incident cases were enrolled. A total of 9,997 patients were recruited, of whom 939 (9.4%) had normal liver biochemistry, 6,210 (62.1%) had chronic hepatitis, 1,940 (19.4%) had liver cirrhosis, and 341 (3.4%) had hepatocellular carcinoma (HCC). In 567 patients (5.7%) the diagnosis was not established. Hepatitis C virus (HCV) was found in 69.9% of the patients and was the only etiological factor…

AdultLiver CirrhosisMaleHepatitis B virusHBsAgCarcinoma HepatocellularCirrhosisalcohol abuseHepatitis C virusHepacivirusChronic liver diseasemedicine.disease_causeRisk FactorsVirologyPrevalencemedicineHBVHumansAgedbusiness.industryIncidenceLiver DiseasesLiver NeoplasmsHepatitis CMiddle AgedHepatitis BHepatitis Bmedicine.diseaseHepatitis CVirologyAlcoholismInfectious DiseasesItalyHepatocellular carcinomaChronic DiseaseHCVFemaleViral hepatitisbusiness
researchProduct

Prevalence of acquired resistance mutations in a large cohort of perinatally infected HIV-1 patients

2019

Maleantiretroviral treatmentInfectious Disease TransmissiongenotypeHuman immunodeficiency virus (HIV)Drug ResistanceHIV InfectionsDrug resistancemedicine.disease_causeRetrospective StudieGenotypepol Gene Products Human Immunodeficiency ViruPrevalenceMedicineVerticalHIV InfectionViralpol Gene ProductsYoung adultGeneral MedicineInfectious DiseasesItalyMutation (genetic algorithm)FemaleHuman Immunodeficiency VirusHumanMicrobiology (medical)AdultSettore MED/17 - Malattie InfettiveAdolescentAnti-HIV AgentsYoung AdultAcquired resistanceDrug Resistance ViralHumansvertical HIV transmissionAdolescent; Adult; Anti-HIV Agents; Drug Resistance Viral; Female; HIV Infections; HIV-1; Humans; Italy; Male; Mutation; Prevalence; Retrospective Studies; Young Adult; pol Gene Products Human Immunodeficiency Virus; Infectious Disease Transmission VerticalRetrospective StudiesHIV perinatally infectionbusiness.industryAnti-HIV AgentRetrospective cohort studyVirologyInfectious Disease Transmission VerticalLarge cohortpol Gene Products Human Immunodeficiency VirusDrug resistanceMutationHIV-1Drug resistance; HIV-1; antiretroviral treatment; genotype; vertical HIV transmissionbusiness
researchProduct

Chronic hepatitis B in Italy: New features of an old disease - Approaching the universal prevalence of hepatitis B e antigen-negative cases and the e…

2008

We evaluated 1336 hepatitis B surface antigen-positive subjects consecutively observed in 79 Italian hospitals over a 6-month period. The proportion of hepatitis B e antigen-negative cases was 86.4%, that of patients coinfected with hepatitis D virus was 9.7%, and the rate of patients coinfected with hepatitis C virus was 16.8%. Multiple logistic regression analysis showed that age >49 years, alcohol abuse, and anti-hepatitis D virus and anti-hepatitis C virus positivity were independent predictors of progression to liver cirrhosis. © 2007 by the Infectious Diseases Society of America. All rights reserved.

Liver CirrhosisAdultMaleMicrobiology (medical)medicine.medical_specialtyCirrhosisAdolescentHepatitis D ChronicHepatitis C virusHepacivirusLiver CirrhosiHepacivirusmedicine.disease_causeGastroenterologyVirusFlaviviridaeHepatitis B ChronicSeroepidemiologic StudiesInternal medicinemedicineHumansHepatitis B e AntigensAgedAged 80 and overCross-Sectional StudieHepacivirubiologybusiness.industrySeroepidemiologic StudieHepatitis Delta ViruHepatitis BMiddle Agedmedicine.diseasebiology.organism_classificationHepatitis DVirologyAlcoholismCross-Sectional StudiesInfectious DiseasesItalyDisease ProgressionFemaleHepatitis B e AntigenHepatitis D virusHepatitis Delta VirusbusinessHuman
researchProduct

Prioritization of high-cost new drugs for HCV: making sustainability ethical

2016

Hepatitis C virus (HCV) infection is a major health problem worldwide. Chronic HCV infection may in the long run cause cirrhosis, hepatic decompensation and hepatocellular carcinoma, with an ultimate disease burden of at least 350,000 deaths per year worldwide. The new generation of highly effective direct acting antivirals (DAA) to treat HCV infection brings major promises to infected patients in terms of exceedingly high rates of sustained virological response (SVR) but also of tolerability, allowing even the sickest patients to be treated. Even in the face of the excellent safety and efficacy and wide theoretical applicability of these regimens, their introduction is currently facing cos…

Carcinoma HepatocellularHealth PrioritiesLiver NeoplasmsInterferon-alphaHepacivirusHepatitis C ChronicAntiviral AgentsHepatitis CDrug CostsSettore MED/02 - Storia Della MedicinaAccess to care cirrhosis Direct acting antivirals Distributive justice Ethics Hepatitis C Hepatocellular carcinoma PrioritizationSettore MED/43 - Medicina LegaleQuality of LifeAnimalsHumansDrug Therapy Combinationhepatitis C
researchProduct